Journal Article

Prospective Study of Mesothelioma Mortality in Turkish Villages With Exposure to Fibrous Zeolite

Y. Izzettin Baris and Philippe Grandjean

in JNCI: Journal of the National Cancer Institute

Volume 98, issue 6, pages 414-417
Published in print March 2006 | ISSN: 0027-8874
Published online March 2006 | e-ISSN: 1460-2105 | DOI: http://dx.doi.org/10.1093/jnci/djj106

Show Summary Details

Preview

Mesothelioma incidence is high in certain villages on the Anatolian plateau in Turkey, where environmental exposure includes erionite, a form of zeolite fibers, from the local volcanic tuff. Previous studies of this exposure were cross-sectional or with a follow-up period of only a few years. A prospective study of residents of two exposed and one nearby control village was initiated in 1979 and continued through December 31, 2003. A total of 891 men and women, aged 20 years or older, were included, 230 of them residing in the village without known exposure to erionite. Mortality data were obtained from hospital records and death certificates. During the 23-year follow-up, 372 deaths occurred; 119 of these were from mesothelioma, which was the cause of 44.5% of all deaths in the exposed villages. Seventeen patients had peritoneal mesothelioma; the rest had pleural mesothelioma. Only two cases of mesothelioma, one of each type, occurred in the control village—both in women born elsewhere. When standardized to the world population, the pleural mesothelioma incidence was approximately 700 and 200 cases per 100 000 people annually in the two exposed villages and about 10 cases per 100 000 people in the control village. When we used Danish data for comparison, the standardized pleural mesothelioma mortality rate was 485 (95% confidence interval = 395 to 590). Our results emphasize the severity of the mesothelioma endemic in erionite-exposed areas of Turkey and call for intensified prevention of mesothelioma by limiting environmental  exposures to these fibers.

Journal Article.  2672 words. 

Subjects: Medical Oncology

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.